Completed PHASE2 INTERVENTIONAL 4-arm NCT00616161

A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function (HORIZON-HF)

A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function

Sponsor: MDS Pharma Services

Conditions Heart Failure

Interventions Istaroxime Placebo

Updated 4 times since 2017 Last updated: Feb 5, 2008 Started: Aug 31, 2006 Primary completion: Jul 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Heart Failure and is currently completed. MDS Pharma Services leads this study, which shows 4 recorded versions since 2006 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MDS Pharma Services
sigma-tau i.f.r. S.p.A.

Data source: sigma-tau i.f.r. S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.